Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers

NCT07024784 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07024784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07024784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Recruiting
Start date
July 30, 2025
Completion date
February 29, 2028
Enrollment
377 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, gynecologic cancers, platinum-sensitive ovarian cancer, primary peritoneal cancer (psoc)